Payment overview · 2025
General Payments
$2,523.30
57 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Oneka, DO
Allopathic & Osteopathic Physicians|Family Medicine · MUSKEGON, MI · NPI 1366457129
Verified facts
What the public records show
CMS Open Payments records show Michael Oneka, DO received $2,523.30 in general payments during 2025 across 57 reported records.
Gilead Sciences, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $579.98 | 23.0% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $367.36 | 14.6% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $301.93 | 12.0% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $277.37 | 11.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $216.20 | 8.6% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.91 | 6.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $138.71 | 5.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $136.04 | 5.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $110.37 | 4.4% | 1 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $107.41 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.04 | 2.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.72 | 1.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.68 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,523.30 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $301.93 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $277.37 | 9 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $213.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $170.91 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.84 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $138.71 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $137.52 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $136.04 | 4 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $117.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.37 | 1 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $107.41 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $103.47 | 3 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $90.96 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $87.33 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.36 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.04 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.04 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
298 | 91 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
124 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 344 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 102 |
| Jardiance | Empagliflozin | 298 | 91 |
| Metformin Hcl | Metformin Hcl | 289 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 70 |
| Lisinopril | Lisinopril | 230 | 74 |
| Gabapentin | Gabapentin | 209 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 38 |
| Losartan Potassium | Losartan Potassium | 132 | 41 |
| Naproxen | Naproxen | 129 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 43 |
| Trulicity | Dulaglutide | 124 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 37 |
| Januvia | Sitagliptin Phosphate | 91 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 19 |
| Pregabalin | Pregabalin | 83 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 22 |
| Celecoxib | Celecoxib | 74 | 32 |
| Omeprazole | Omeprazole | 74 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 20 |
| Tramadol Hcl | Tramadol Hcl | 72 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Baclofen | Baclofen | 67 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 28 |
| Famotidine | Famotidine | 64 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Trazodone Hcl | Trazodone Hcl | 59 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 19 |
| Farxiga | Dapagliflozin Propanediol | 57 | 17 |
| Allopurinol | Allopurinol | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 18 |
| Atenolol | Atenolol | 52 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 49 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 19 |
| Ibuprofen | Ibuprofen | 45 | 11 |
| Carvedilol | Carvedilol | 44 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 13 |
| Eliquis | Apixaban | 42 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | 12 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Prednisone | Prednisone | 19 | 15 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,523.30 · 57 records | Gilead Sciences, Inc. | AIRSUPRA, ANZUPGO, APRETUDE, Auvelity, Biktarvy, CABENUVA, CAPLYTA, COBENFY, DOVATO, FANAPT, Kerendia, MOUNJARO, Ozempic, REXULTI, RUKOBIA, Rybelsus, VOQUEZNA, VRAYLAR, Wegovy, Yeztugo, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error